tiprankstipranks
Trending News
More News >
NewAmsterdam Pharma Company (NAMS)
NASDAQ:NAMS
US Market
Advertisement

NewAmsterdam Pharma Company (NAMS) Income Statement

Compare
239 Followers

NewAmsterdam Pharma Company Income Statement

Last quarter (Q3 2025), NewAmsterdam Pharma Company's total revenue was $348.00K, a decrease of -98.80% from the same quarter last year. In Q3, NewAmsterdam Pharma Company's net income was $-72.00M. See NewAmsterdam Pharma Company’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 45.56M$ 14.09M$ 102.69M$ 0.00$ 0.00
Gross Profit
$ 45.56M$ 14.09M$ 102.69M$ 0.00$ 0.00
Operating Expenses
$ 221.85M$ 197.06M$ 106.25M$ 34.98M$ 6.63M
Depreciation and Amortization
$ 113.00K$ 49.00K$ 9.00K$ 5.00K$ 1.22K
EBITDA
$ -241.49M$ -176.86M$ -22.34M$ -41.37M$ -6.63M
Operating Income
$ -176.29M$ -182.97M$ -3.56M$ -34.98M$ -6.63M
Other Income/Expenses
$ -65.31M$ 6.06M$ -19.08M$ -6.81M$ -390.91K
Pretax Income
$ -241.60M$ -176.91M$ -22.63M$ -41.78M$ -7.02M
Net Income
$ -241.60M$ -176.94M$ -22.63M$ -41.78M$ -7.02M
Per Share Metrics
Basic EPS
$ -2.56$ -2.15$ -1.11$ -3.34$ -1.15
Diluted EPS
$ -2.56$ -2.15$ -1.11$ -3.34$ -1.15
Weighted Average Shares Outstanding
94.36M 82.16M 18.97M 17.75M 17.75M
Weighted Average Shares Outstanding (Diluted)
94.36M 82.16M 18.97M 17.75M 17.75M
Currency in USD

NewAmsterdam Pharma Company Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis